Tags

Type your tag names separated by a space and hit enter

Medium-dose 308-nm excimer laser for the treatment of psoriasis.
J Am Acad Dermatol 2002; 47(5):701-8JA

Abstract

BACKGROUND

The excimer laser delivers targeted ultraviolet B 308-nm radiation.

OBJECTIVE

This investigation evaluated the efficacy of multiple, medium-dose excimer 308-nm laser treatments for psoriasis.

METHODS

Twenty volunteers with plaque psoriasis were enrolled. Six plaques received treatment 3 times per week for up to 8 weeks; another plaque served as a control. As in standard phototherapy, a flexible dose escalation scheme was implemented during the course of treatment. Modified Psoriasis Area and Severity Index scores were rendered throughout the study with follow-ups at 1, 2, 4, and 6 months.

RESULTS

Fifteen subjects completed the study without complications. The mean number of treatments to achieve >95% clearance was 10.6. The mean cumulative UV radiation dose was 6.1 J/cm(2), and the mean remission time was 3.5 months.

CONCLUSION

A thrice-weekly, medium-dose irradiation schedule with the 308-nm laser can effectively clear localized plaque-type psoriasis in fewer treatments with an overall lower cumulative dose, compared with standard phototherapy. This innovative UV device allows specific targeting of affected sites without needless exposure of unaffected skin.

Authors+Show Affiliations

Gange Photomedicine Research Center, Wellman Laboratories of Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12399761

Citation

Trehan, Manju, and Charles R. Taylor. "Medium-dose 308-nm Excimer Laser for the Treatment of Psoriasis." Journal of the American Academy of Dermatology, vol. 47, no. 5, 2002, pp. 701-8.
Trehan M, Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol. 2002;47(5):701-8.
Trehan, M., & Taylor, C. R. (2002). Medium-dose 308-nm excimer laser for the treatment of psoriasis. Journal of the American Academy of Dermatology, 47(5), pp. 701-8.
Trehan M, Taylor CR. Medium-dose 308-nm Excimer Laser for the Treatment of Psoriasis. J Am Acad Dermatol. 2002;47(5):701-8. PubMed PMID: 12399761.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Medium-dose 308-nm excimer laser for the treatment of psoriasis. AU - Trehan,Manju, AU - Taylor,Charles R, PY - 2002/10/26/pubmed PY - 2002/11/26/medline PY - 2002/10/26/entrez SP - 701 EP - 8 JF - Journal of the American Academy of Dermatology JO - J. Am. Acad. Dermatol. VL - 47 IS - 5 N2 - BACKGROUND: The excimer laser delivers targeted ultraviolet B 308-nm radiation. OBJECTIVE: This investigation evaluated the efficacy of multiple, medium-dose excimer 308-nm laser treatments for psoriasis. METHODS: Twenty volunteers with plaque psoriasis were enrolled. Six plaques received treatment 3 times per week for up to 8 weeks; another plaque served as a control. As in standard phototherapy, a flexible dose escalation scheme was implemented during the course of treatment. Modified Psoriasis Area and Severity Index scores were rendered throughout the study with follow-ups at 1, 2, 4, and 6 months. RESULTS: Fifteen subjects completed the study without complications. The mean number of treatments to achieve >95% clearance was 10.6. The mean cumulative UV radiation dose was 6.1 J/cm(2), and the mean remission time was 3.5 months. CONCLUSION: A thrice-weekly, medium-dose irradiation schedule with the 308-nm laser can effectively clear localized plaque-type psoriasis in fewer treatments with an overall lower cumulative dose, compared with standard phototherapy. This innovative UV device allows specific targeting of affected sites without needless exposure of unaffected skin. SN - 0190-9622 UR - https://www.unboundmedicine.com/medline/citation/12399761/Medium_dose_308_nm_excimer_laser_for_the_treatment_of_psoriasis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190962202001494 DB - PRIME DP - Unbound Medicine ER -